PharmaLinea’s >Your< UTI Free Sachets shown to improve standard antibiotic therapy and resolve recurrence

>Your< UTI Free Sachets alleviates the issue of recurrent UTIs in women

PharmaLinea has announced the publication of a new clinical study addressing one of the most pressing global health issues for women – recurring urinary tract infections (UTIs). UTIs are highly prevalent and persistent. Standard antibiotic treatment, while efficient at clearing the infection, often fails to prevent relapses. In the newly published study, the addition of >Your< UTI Free Sachets to antibiotic treatment resulted in a significantly lower frequency of relapses and a significantly higher quality of life when compared to drug treatment alone. The study and product thus empower women to take control of their health and resolve an issue that previously lacked credible solutions.

UTIs affect around 400 million people yearly and about 50% of women suffer from UTIs at least once in their lifetime. The majority of patients are prescribed antibiotics, which are efficient at clearing the infection, but often fail at preventing recurrence. Some 30% of women affected by a UTI experience at least one recurrent infection. Chronic UTI can impact on the patients’ quality of life with limited solutions. While cranberry juices, teas, and commodity-based supplements do not have clinical proof of efficacy, doctors and pharmacists lack prescriptions to avoid chronic urinary tract issues and chronic antibiotic use.

“Recurrent infections are not only an immediate issue for the consumer but can have larger implications. Repeating UTIs and subsequent prescriptions of antibiotics can lead to antibiotic resistance – one of the most pressing global issues. The WHO’s “Global action plan on antimicrobial resistance” includes two strategic goals: to reduce the incidence of infection and to optimise antimicrobial medicine use. With our product and the presented clinical trial, we aimed to support both those goals,“ stated Maja Orešnik, science and research director at PharmaLinea.

The clinical trial aimed to evaluate the efficacy and safety of >Your< UTI Free Sachets in women with acute cystitis and their effect on the recurrence of lower UTIs. The study included 98 female patients aged 18-80 years with active acute cystitis, which was confirmed by a positive bacteriological urine test. The participants were randomised into two groups. Both groups received standard antibiotic therapy, while the study group additionally received >Your< UTI Free Sachets. The trial lasted 12 weeks and aimed to measure the frequency of disease relapses and assess quality of life improvements.

The trial was organised and conducted by Petrovax. Uronext is the commercial B2C brand name under which >Your< UTI Free Sachets were launched and studied.

The addition of >Your< UTI Free Sachets to standard antibiotic therapy resulted in a lower frequency of relapses and higher quality of life when compared to antibiotic treatment alone. Key figures of the study group, when compared to control, demonstrated that >Your< UTI Free Sachets presented over four times lower the chance of relapse; a median recurrence rate of zero; and over 20% higher improvement in quality of life.

The frequency of relapses in the study group was over four times lower when compared to the control group. The recurrence rate in the study group was 3.7 times lower than in the control group. While the median number of recurrences per person in the control group was one, the infection did not recur at all in the majority of the study group. The study group also reported a 20% higher improvement in quality of life during the first week of supplementation when compared to the control group. The compliance in the study group was 98%.

With the trial’s results, healthcare professionals can have a solution minimising UTI relapse. Women with chronic UTI have access to a lasting treatment, leading to an improved quality of life. Brand owners, in turn, have a proven product they can promote through healthcare professionals, distinguishing them from competitors. Not only one but two clinical studies have now been completed on the product, adding credibility.

“Already a commercial success, the product has secured the number one spot in two European markets and has been launched by brand owners in multiple markets across Europe, Asia, LATAM, and the Middle East. The new clinical data is bound to only increase the opportunity, “ said Jernej Klopčič, PharmaLinea’s business development director.

“It is a great example of how nutraceutical solutions can not only prevent or help with recovery but also complement traditional pharmaceutical products to improve treatment. Of course, there are other UTI supplements on the market but few have clinically supported efficacy and are thus relatively useless to urologists. Our UTI products are a unique combination of our own proprietary whole-fruit cranberry ingredient Qcran, a clinically relevant dose of D-mannose, and microencapsulated vitamin D3, packed in a single sachet. Qcran is one of the few if not only cranberry ingredient that is 100% whole fruit, without any sort of extraction taking place. This is achieved through a unique cold fusion production process. The resulting product retains all the beneficial properties of cranberries, including a very high fibre content, higher than any other cranberry ingredient we’ve tested. This results in the active ingredient PAC being protected, released into the bloodstream in a sustained manner, and ultimately having higher efficacy. Clinical trials are relatively rare for finished products in supplements and even more so for private label products. The investment in extensive scientific support of the product was made to empower both women and doctors with an important tool for prevention and care, “ commented PharmaLinea’s marketing director, Matevž Ambrožič.